Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTI Bags Cash, Turns Its Back On Zevalin

This article was originally published in The Pink Sheet Daily

Executive Summary

Buyer Spectrum downplays supplemental BLA delay in front-line non-Hodgkins lymphoma.

You may also be interested in...



Deals Of The Week: Amgen/Micromet, Celgene/Avila, Watson/Ascent

Along with three biotech acquisitions, the week in deal-making also saw the licensing of a new hepatitis C candidate with a different mechanism of action, further consolidation in the animal health field, and the end of Ipsen and Santhera’s collaboration on Alzheimer’s drug fipamezole.

Cancer Drug Zevalin May Finally Thrive Under Spectrum

The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.

Cancer Drug Zevalin May Finally Thrive Under Spectrum

The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.

Related Content

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel